Matches in SemOpenAlex for { <https://semopenalex.org/work/W2260474133> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2260474133 endingPage "4103" @default.
- W2260474133 startingPage "4103" @default.
- W2260474133 abstract "4103 Background: GEM is the most active single agent in the treatment of pancreatic carcinoma. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor. Recent studies in human pancreatic tumor cell lines suggest an involvement of COX-2 in the control of tumor-dependent angiogenesis and provide the rational for inhibition of the COX pathway as an effective therapeutic approach for pancreatic cancer. The aim of this study is to evaluate the toxicity, safety and efficacy of this combination regimen. Methods: From January 2001 to July 2002, 32 consecutive patients (18 male/14 female) entered the trial. Median age was 63 years (range 48–76), median PS 1 (range 0–2); 22 patients (pts) were metastatic, 10 pts had locally advanced disease. Median basal CA19.9 value was 747 U/mL (range 1–50000). A total number of 210 cycles (median 6,5 per patient; range 2–12) were administered. The schedule consisted of GEM 1000 mg/m2 (as a 30 minutes iv infusion) on days 1,8 every 3 weeks and Celecoxib 400 mg bid. Results: Grade 3 NCI-CTC haematological toxicity was neutropenia in 9% of pts. Neither grade 4 neutropenia nor grade 3–4 thrombocytopenia were observed. Grade 3 non-haematological toxicity was as follows: hepatic toxicity 9%, nausea 3%. Although the high dose of celecoxib, neither gastric toxicity nor renal failure were observed. Only 3 pts (9%) had a minimum creatinine increase. Clinical benefit was obtained in 46% of pts, 38% had no basal pain and 16% didn't achieve any symptom control. Median survival was 9,1 months; 1-year survival rate was 36%. Conclusions: The goals we achieved with celecoxib-GEM combination are very low toxicity, good quality of life and improved overall survival. Accrual is ongoing. No significant financial relationships to disclose." @default.
- W2260474133 created "2016-06-24" @default.
- W2260474133 creator A5002769621 @default.
- W2260474133 creator A5008861188 @default.
- W2260474133 creator A5011091694 @default.
- W2260474133 creator A5020684039 @default.
- W2260474133 creator A5030116253 @default.
- W2260474133 creator A5032959397 @default.
- W2260474133 creator A5041800281 @default.
- W2260474133 creator A5043367155 @default.
- W2260474133 creator A5084574967 @default.
- W2260474133 creator A5086312742 @default.
- W2260474133 date "2004-07-15" @default.
- W2260474133 modified "2023-10-14" @default.
- W2260474133 title "Gemcitabine (Gem) plus celecoxib in advanced pancreatic carcinoma: a phase II study" @default.
- W2260474133 doi "https://doi.org/10.1200/jco.2004.22.90140.4103" @default.
- W2260474133 hasPublicationYear "2004" @default.
- W2260474133 type Work @default.
- W2260474133 sameAs 2260474133 @default.
- W2260474133 citedByCount "0" @default.
- W2260474133 crossrefType "journal-article" @default.
- W2260474133 hasAuthorship W2260474133A5002769621 @default.
- W2260474133 hasAuthorship W2260474133A5008861188 @default.
- W2260474133 hasAuthorship W2260474133A5011091694 @default.
- W2260474133 hasAuthorship W2260474133A5020684039 @default.
- W2260474133 hasAuthorship W2260474133A5030116253 @default.
- W2260474133 hasAuthorship W2260474133A5032959397 @default.
- W2260474133 hasAuthorship W2260474133A5041800281 @default.
- W2260474133 hasAuthorship W2260474133A5043367155 @default.
- W2260474133 hasAuthorship W2260474133A5084574967 @default.
- W2260474133 hasAuthorship W2260474133A5086312742 @default.
- W2260474133 hasConcept C121608353 @default.
- W2260474133 hasConcept C126322002 @default.
- W2260474133 hasConcept C141071460 @default.
- W2260474133 hasConcept C143998085 @default.
- W2260474133 hasConcept C2776467144 @default.
- W2260474133 hasConcept C2777063308 @default.
- W2260474133 hasConcept C2780210213 @default.
- W2260474133 hasConcept C2780258809 @default.
- W2260474133 hasConcept C2780580376 @default.
- W2260474133 hasConcept C2781413609 @default.
- W2260474133 hasConcept C29730261 @default.
- W2260474133 hasConcept C31760486 @default.
- W2260474133 hasConcept C71924100 @default.
- W2260474133 hasConcept C90924648 @default.
- W2260474133 hasConceptScore W2260474133C121608353 @default.
- W2260474133 hasConceptScore W2260474133C126322002 @default.
- W2260474133 hasConceptScore W2260474133C141071460 @default.
- W2260474133 hasConceptScore W2260474133C143998085 @default.
- W2260474133 hasConceptScore W2260474133C2776467144 @default.
- W2260474133 hasConceptScore W2260474133C2777063308 @default.
- W2260474133 hasConceptScore W2260474133C2780210213 @default.
- W2260474133 hasConceptScore W2260474133C2780258809 @default.
- W2260474133 hasConceptScore W2260474133C2780580376 @default.
- W2260474133 hasConceptScore W2260474133C2781413609 @default.
- W2260474133 hasConceptScore W2260474133C29730261 @default.
- W2260474133 hasConceptScore W2260474133C31760486 @default.
- W2260474133 hasConceptScore W2260474133C71924100 @default.
- W2260474133 hasConceptScore W2260474133C90924648 @default.
- W2260474133 hasIssue "14_suppl" @default.
- W2260474133 hasLocation W22604741331 @default.
- W2260474133 hasOpenAccess W2260474133 @default.
- W2260474133 hasPrimaryLocation W22604741331 @default.
- W2260474133 hasRelatedWork W1993844652 @default.
- W2260474133 hasRelatedWork W2008828217 @default.
- W2260474133 hasRelatedWork W2136383268 @default.
- W2260474133 hasRelatedWork W2147065585 @default.
- W2260474133 hasRelatedWork W2160354293 @default.
- W2260474133 hasRelatedWork W2170588003 @default.
- W2260474133 hasRelatedWork W2352825293 @default.
- W2260474133 hasRelatedWork W2410090482 @default.
- W2260474133 hasRelatedWork W3041653713 @default.
- W2260474133 hasRelatedWork W332524067 @default.
- W2260474133 hasVolume "22" @default.
- W2260474133 isParatext "false" @default.
- W2260474133 isRetracted "false" @default.
- W2260474133 magId "2260474133" @default.
- W2260474133 workType "article" @default.